Showing results (211-220 of 233) with videos related to

Sort By:
Pageof 24
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trialL Paz-Ares, A Spira, D Raben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2023
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerH Borghaei, F de Marinis, D Dumoulin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) programC Leduc, J P Merlio, B Besse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trialB Besse, J Mazières, L Ribassin-Majed, et al.
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2023
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trialJ Remon, B Besse, S Ponce Aix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2023
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1B Besse, E Felip, R Garcia Campelo, et al.
Pageof 24